These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39036375)

  • 1. Durable clinical response to the multidisciplinary management of neurosurgery, radiation and chemoimmunotherapy in a patient with PD-L1/PD-L2/JAK2 (PDJ)-amplified, refractory triple-negative breast cancer.
    Zhao H; Ma W; Fragoso RC; Iv GRH; Ashok A; Li T
    J Natl Cancer Cent; 2021 Sep; 1(3):115-121. PubMed ID: 39036375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eganelisib combined with immune checkpoint inhibitor therapy and chemotherapy in frontline metastatic triple-negative breast cancer triggers macrophage reprogramming, immune activation and extracellular matrix reorganization in the tumor microenvironment.
    O'Connell BC; Hubbard C; Zizlsperger N; Fitzgerald D; Kutok JL; Varner J; Ilaria R; Cobleigh MA; Juric D; Tkaczuk KHR; Elias A; Lee A; Dakhil S; Hamilton E; Soliman H; Peluso S
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39214650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current treatment landscape for patients with locally recurrent inoperable or metastatic triple-negative breast cancer: a systematic literature review.
    Li CH; Karantza V; Aktan G; Lala M
    Breast Cancer Res; 2019 Dec; 21(1):143. PubMed ID: 31842957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.
    Barrett MT; Anderson KS; Lenkiewicz E; Andreozzi M; Cunliffe HE; Klassen CL; Dueck AC; McCullough AE; Reddy SK; Ramanathan RK; Northfelt DW; Pockaj BA
    Oncotarget; 2015 Sep; 6(28):26483-93. PubMed ID: 26317899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDJ amplicon in triple negative breast cancer.
    Roesler AS; Malasi S; Koslosky L; Hartmayer P; Naab TJ; Carter JM; Zahrieh D; Hillman D; Leon-Ferre RA; Couch FJ; Goetz MP; Anderson KS; Pockaj BA; Barrett MT
    Sci Rep; 2023 Jan; 13(1):618. PubMed ID: 36635351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
    Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
    J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
    Badve SS; Penault-Llorca F; Reis-Filho JS; Deurloo R; Siziopikou KP; D'Arrigo C; Viale G
    J Natl Cancer Inst; 2022 May; 114(5):664-675. PubMed ID: 34286340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Atezolizumab Monotherapy or Combined Therapy with Chemotherapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Alimohammadi M; Faramarzi F; Mafi A; Mousavi T; Rahimi A; Mirzaei H; Asemi Z
    Curr Pharm Des; 2023; 29(31):2461-2476. PubMed ID: 37921135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
    Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
    J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Retreatment of Metastatic Triple-negative Breast Cancer With Immune Checkpoint Inhibitors and Chemotherapy.
    Nozaki Y; Yamamuro M; Tanaka N; Kamo N; Konishi J
    Cancer Diagn Progn; 2023; 3(3):387-391. PubMed ID: 37168973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
    Adams S; Loi S; Toppmeyer D; Cescon DW; De Laurentiis M; Nanda R; Winer EP; Mukai H; Tamura K; Armstrong A; Liu MC; Iwata H; Ryvo L; Wimberger P; Rugo HS; Tan AR; Jia L; Ding Y; Karantza V; Schmid P
    Ann Oncol; 2019 Mar; 30(3):405-411. PubMed ID: 30475947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer.
    Kyte JA; Røssevold A; Falk RS; Naume B
    J Transl Med; 2020 Jun; 18(1):252. PubMed ID: 32576225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Miles D; Gligorov J; André F; Cameron D; Schneeweiss A; Barrios C; Xu B; Wardley A; Kaen D; Andrade L; Semiglazov V; Reinisch M; Patel S; Patre M; Morales L; Patel SL; Kaul M; Barata T; O'Shaughnessy J;
    Ann Oncol; 2021 Aug; 32(8):994-1004. PubMed ID: 34219000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of immunotherapy to chemotherapy for metastatic triple-negative breast cancer: A systematic review and meta-analysis of randomized clinical trials.
    Huo X; Shen G; Liu Z; Liang Y; Li J; Zhao F; Ren D; Zhao J
    Crit Rev Oncol Hematol; 2021 Dec; 168():103530. PubMed ID: 34801695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
    Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
    Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 immune checkpoint inhibitors in metastatic triple-negative breast cancer: a systematic review and meta-analysis.
    Yu Y; Jin X; Zhu X; Xu Y; Si W; Zhao J
    Front Immunol; 2023; 14():1206689. PubMed ID: 37377959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
    Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R
    JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.